Based on the Zimmer Biomet Holdings Inc stock forecast from 17 analysts, the average analyst target price for Zimmer Biomet Holdings Inc is USD 123.15 over the next 12 months. Zimmer Biomet Holdings Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Zimmer Biomet Holdings Inc is Bullish , which is based on 10 positive signals and 4 negative signals. At the last closing, Zimmer Biomet Holdings Inc’s stock price was USD 108.85. Zimmer Biomet Holdings Inc’s stock price has changed by +0.15% over the past week, +3.83% over the past month and +0.72% over the last year.
No recent analyst target price found for Zimmer Biomet Holdings Inc
No recent average analyst rating found for Zimmer Biomet Holdings Inc
Company Overview Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. Read Less
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologic...Read More
Frequently Asked Questions About Zimmer Biomet Holdings Inc (ZBH) Stock
Based on ratings from 17 analysts Zimmer Biomet Holdings Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 11 buy, 1 sell and 19 hold ratings.
ZBH stock's dividend yield is 0.90%.
Our analysis grades ZBH stock's dividend yield at F. This means that ZBH stock's dividend yield is above 17% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ZBH may be a poor dividend stock for its sector.
Based on targets from 17 analysts, the average taret price for ZBH is USD 123.15 over the next 12 months. The maximum analyst target price is USD 155 while the minimum anlayst target price is USD 107.
ZBH stock's Price/Earning ratio is 20.40.
Our analysis grades ZBH stock's Price / Earning ratio at B+. This means that ZBH stock's Price/Earning ratio is above 11% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ZBH may be undervalued for its sector.
The last closing price of ZBH's stock was USD 108.85.
The most recent market capitalization for ZBH is USD 21.28B.
Based on targets from 17 analysts, the average taret price for ZBH is projected at USD 123.15 over the next 12 months.
This means that ZBH's stock price may go up by +13.13% over the next 12 months.
We can't find any ETFs which contains Zimmer Biomet Holdings Inc's stock.
As per our most recent records Zimmer Biomet Holdings Inc has 18,000 Employees.
Zimmer Biomet Holdings Inc's registered address is 345 East Main Street, Warsaw, IN, United States, 46580.
You can get more information about it from Zimmer Biomet Holdings Inc's website at https://www.zimmerbiomet.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Zimmer Biomet Holdings Inc (ZBH) Stock
Based on ratings from 17 analysts Zimmer Biomet Holdings Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bullish . The stock has 11 buy, 1 sell and 19 hold ratings.
ZBH stock's dividend yield is 0.90%.
Our analysis grades ZBH stock's dividend yield at F. This means that ZBH stock's dividend yield is above 17% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ZBH may be a poor dividend stock for its sector.
Based on targets from 17 analysts, the average taret price for ZBH is USD 123.15 over the next 12 months. The maximum analyst target price is USD 155 while the minimum anlayst target price is USD 107.
ZBH stock's Price/Earning ratio is 20.40.
Our analysis grades ZBH stock's Price / Earning ratio at B+. This means that ZBH stock's Price/Earning ratio is above 11% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this ZBH may be undervalued for its sector.
The last closing price of ZBH's stock was USD 108.85.
The most recent market capitalization for ZBH is USD 21.28B.
Based on targets from 17 analysts, the average taret price for ZBH is projected at USD 123.15 over the next 12 months.
This means that ZBH's stock price may go up by +13.13% over the next 12 months.
We can't find any ETFs which contains Zimmer Biomet Holdings Inc's stock.
As per our most recent records Zimmer Biomet Holdings Inc has 18,000 Employees.
Zimmer Biomet Holdings Inc's registered address is 345 East Main Street, Warsaw, IN, United States, 46580.
You can get more information about it from Zimmer Biomet Holdings Inc's website at https://www.zimmerbiomet.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ZBH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
